Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type, By Pathogen Targeted, By Age Group, By Route of Administration, By Sales Channel

Description

Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market is estimated to be valued at USD 62,785.9 Thousands in 2026 and is expected to reach USD 115,476.0 Thousands by 2033, growing at a compound annual growth rate (CAGR) of 11.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 62,785.9 Thousands
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.20%	2033 Value Projection:	USD 115,476.0 Thousands

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is expected to grow at a significant rate during the forecast period owing to the increasing burden of recurrent UTIs, growing antimicrobial resistance and the need for alternatives to repeated antibiotic use. The vaccine development is primarily focused on pathogens such as Escherichia coli, with whole-cell, subunit and conjugate approaches gaining interest in the clinical and research pipelines.

The regional market opportunities are dependent on healthcare infrastructure, disease prevalence, regulatory environments and the availability of preventive therapies. Europe and Asia Pacific will continue to be key markets due to mature healthcare systems and increasing clinical development activities whereas Latin America and the Middle East & Africa are emerging markets with growing healthcare access and uptake of novel preventive therapies.

Market Dynamics

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is primarily driven by rising incidence of recurrent UTIs and growing antimicrobial resistance, which is increasing the need for preventive approaches beyond repeated antibiotic treatment. Advances in vaccine research, growing investment in bacterial vaccine candidates, and increasing clinical focus on Escherichia coli and other uropathogens are supporting market development across key regions.

However, a number of constraints are present in the market, such as limited availability of approved UTI vaccines, long clinical development timeframes and uncertain efficacy across a wide range of bacterial strains. Nevertheless, significant opportunities exist in vaccines targeting recurrent and drug-resistant UTIs, particularly among high-risk adult and elderly populations.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include INMUNOTEK S.L., OM Pharma SA, Sequoia Vaccines, Inc., GlaxoSmithKline Biologicals SA, Strathmann GmbH & Co. KG, Legacy Pharmaceuticals Switzerland GmbH, CureVac SE, Janssen-Cilag International NV, Sanofi, and GlycoVaxyn AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market

Market Segmentation

Vaccine Type Insights (Revenue, USD Th, 2021 - 2033)
Bacterial whole-cell Vaccines
Subunit Vaccines
Conjugate Vaccines
Live-Attenuated Vaccines
Others
Pathogen Targeted Insights (Revenue, USD Th, 2021 - 2033)
Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa
Other Targeted Pathogens
Age Group Insights (Revenue, USD Th, 2021 - 2033)
Pediatric
Adults
Elderly
Route of Administration Insights (Revenue, USD Th, 2021 - 2033)
Parenteral
Oral
Sublingual
Intranasal
Sales Channel Insights (Revenue, USD Th, 2021 - 2033)
Hospitals and Clinic Pharmacies
Retail pharmacies
Others
Key Players Insights
INMUNOTEK S.L.
OM Pharma SA
Sequoia Vaccines, Inc.
GlaxoSmithKline Biologicals SA
Strathmann GmbH & Co. KG
Legacy Pharmaceuticals Switzerland GmbH
CureVac SE
Janssen-Cilag International NV
Sanofi
GlycoVaxyn AG

Product Code: CMI10009

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Pathogen Targeted
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Age Group
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Route of Administration
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Sales Channel

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Industry Trends

4. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Bacterial whole-cell Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Subunit Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Conjugate Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Live-Attenuated Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

5. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Pathogen Targeted, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Escherichia coli
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Klebsiella pneumoniae
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Pseudomonas aeruginosa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Other Targeted Pathogens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

6. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Age Group, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Elderly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

7. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Route of Administration, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Sublingual
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

8. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Sales Channel, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals and Clinic Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

9. Competitive Landscape

Company Profile
- INMUNOTEK S.L.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- OM Pharma SA
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sequoia Vaccines, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GlaxoSmithKline Biologicals SA
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Strathmann GmbH & Co. KG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Legacy Pharmaceuticals Switzerland GmbH
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- CureVac SE
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Janssen-Cilag International NV
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GlycoVaxyn AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us